Extracellular Matrix Remodeling of the Umbilical Cord and Placenta in Preeclampsia

NCT01931891 | Unknown

• 1 other identifier: ztb- wharton jelly
• Study Type: observational
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

Preeclampsia affects 2% to 8% of all pregnancies and is a major cause of maternal morbidity an mortality worldwide.Althought the primary pathology leading to preeclampsia is remain not known, complex pathophysiologic pathways and mechanisms have been described. New blood vessels evolve during angiogenesis and vasculogenesis, two physiological processes, that play a crucial role in embryogenesis and placentation. Structural alterations in the human umbilical cord, maternal spiral arteries can cause adverse fetal consequences.Pre-eclampsia is accompanied by an extensive remodelling of the ECM of the umbilical cord. Pre-eclamptic Wharton's jelly contains higher amounts of glycosaminoglycans in comparison to control tissue. Matrixmetalloproteinases (MMPs) are a family of proteolytic enzymes that degrade various components of the extracellular matrix (ECM). A Disintegrin And Metalloproteinases (ADAMs) and ADAMs with Thrombospondin motifs (ADAMTS) are proteinases closely related to Matrix Metalloproteinases (MMPs). Dysregulation of ADAMs and ADAMTS expression have been reported in different types of pathologies such as cancer, osteoarthritis, neurodegenerative inflammation or asthma. The role of ADAMTS in the pathomechanism of pre-eclampsia has not been studied until now. We therefore decided to compare the ADAMTS composition of the umbilical cord and placenta from newborns of mothers with pre-eclampsia with those with normal pregnancy.

Conditions

Alterations of ECM in Umbilical Cord ECM in Preeclampisa; Alterations of ECM in Placenta in Preeclampisa

Keywords

preeclampsia, ADAMTS , wharton jelly, extracellüler matrix, placenta

Outcome Measures

Primary Outcomes (1)

• severe preclampsia

  34 weeks

Study Arms (1)

prreclampsia

Eligibility Criteria

• Age: 18 Years - 39 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

preeclamptic women

You may qualify if:

• Clinical diagnosis of preeclampsia (diagnosed per ACOG criteria)

You may not qualify if:

• known chronic disease multipl pregnancies

Sponsors & Collaborators

• Zekai Tahir Burak Women's Health Research and Education Hospital: lead
• Turgut Ozal University: collaborator

Study Sites (1)

Zekai Tahir Burak Maternity Hospital

Ankara, Turkey (Türkiye)

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

umbilical cord placenta

MeSH Terms

Conditions

Pre-Eclampsia

Condition Hierarchy (Ancestors)

Hypertension, Pregnancy-Induced; Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases

Study Officials

• ayse kirbas, md

  zekai tahir burak hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

ayse kirbas, md

CONTACT

533-646-9213; ayseozdemirkirbas@hotmail.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Zekai Tahir Burak Maternity and Teaching Hospital

Study Record Dates

• First Submitted: August 26, 2013
• First Posted: August 29, 2013
• Study Start: July 1, 2013
• Primary Completion: February 1, 2014
• Study Completion: July 1, 2014
• Last Updated: August 30, 2013

Record last verified: 2013-07

Locations

TU (1)